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Background/Aims: Anemia in patients with inflammatory 
bowel disease significantly affects the quality of life. The aim 
of this study was to investigate the frequency of and risk fac-
tors for anemia and to describe the management of anemia 
in patients with intestinal Behçet’s disease (BD) in actual 
clinical practice. Methods: We included 64 patients with 
intestinal BD who visited the outpatient clinic of a tertiary re-
ferral center in June 2011 and had available laboratory data 
for the subsequent 6 months. Results: Anemia was detected 
in 26 patients (40.6%). After 6 months, anemia was still 
present in 14 of these patients (53.8%). The cause of ane-
mia was investigated in eight patients (30.8%), and oral iron 
supplementation was prescribed to four patients (15.4%). Of 
these four patients, two (50%) recovered completely within 
6 months. Anemia was associated with a high Disease Activ-
ity Index for Intestinal Behçet’s Disease (DAIBD, p=0.024), 
erythrocyte sedimentation rate (p=0.003), and C-reactive 
protein (p=0.049) in univariate analysis. In multivariate 
analysis, the factor predictive for anemia in patients with in-
testinal BD was a higher DAIBD (≥40; odds ratio, 4.08; 95% 
confidence interval, 1.21 to 13.71; p=0.023). Conclusions: 
Although anemia is common in intestinal BD patients, its 
clinical importance is overlooked in daily practice. Moderate 
to severe disease activity is predictive of anemia. (Gut Liver 
2015;9:750-755)
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INTRODUCTION
Behçet’s disease (BD), which can cause chronic gastrointes-
tinal (GI) inflammation, is a chronically relapsing multisystem 
vasculitis, characterized by recurrent oral and genital ulcers, 
ocular lesions, skin manifestations, arthritis, and vascular, neu-
rologic, and intestinal involvements.1 Because GI involvement 
can cause severe morbidity and mortality, BD is designated “in-
testinal BD” if GI symptoms predominate and typical ulcerative 
GI lesions are objectively documented.2-4 The frequency of GI 
involvement ranges from 3% to 50% and varies depending on 
geographic location.5,6 The most frequently affected site is the 
ileocecal region, which presents with symptoms of abdominal 
pain, diarrhea, and bleeding.7,8
The prevalence of anemia in patients with inflammatory 
bowel disease (IBD) including Crohn’s disease (CD) and ulcer-
ative colitis (UC) ranges from 8.8% to 73.7%, depending on the 
patient subpopulation.9-11 It has been considered an important 
factor affecting patient quality of life.11 There have been a sub-
stantial number of studies on the epidemiology, risk factors and 
treatments of anemia in CD and UC.12-14
Among IBD patients, iron-deficiency anemia is the most 
common cause of anemia, and is usually manageable through 
medication. Iron deficiency is caused by iron malabsorption 
due to active disease, dietary restrictions, or intestinal bleeding. 
Moreover, in IBD patients, chronic intestinal inflammation leads 
to the upregulation of both proinflammatory cytokines (e.g., 
interleukin [IL]-1β, IL-6) and hepcidin, which results in impaired 
intestinal iron uptake from the gut and impaired iron sequester-
ing in the reticuloendothelial system.15-17 In addition, anemia in 
IBD patients can occur due to treatment. Therapy with sulfasala-
zine or 5-aminosalicylic acid has been related to a minor degree 
of hemolysis or aplasia.18 Moreover, both 6-mercaptopurine and 
azathioprine have a direct myelosuppressive effect.19 In addi-
tion to these possible causes of anemia in IBD, BD, as a type of 
vasculiits, has the characteristic that reactive oxygen species are 
produced endogenously at sites of endothelial inflammation by 
activated leukocytes and it could cause anemia.20
Unlike CD and UC, there have been no study on anemia in 
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patients with intestinal BD; therefore, in this study, we sought to 
establish the frequency of anemia and describe its management 
in patients with intestinal BD in actual clinical practice.
MATERIALS AND METHODS
1. Study design and patients
A cross-sectional study was performed based on well-orga-
nized electronic medical records. We included 77 patients with 
intestinal BD who had attended the outpatient clinic of a ter-
tiary referral medical center between June 1, 2011 and June 30, 
2011. Among them, we excluded 13 patients based on presence 
of hematologic malignancy or other severe comorbidities, or 
loss to 6-month follow-up to investigate not only the causes of 
anemia, but also treatment agents and the results of treatments 
after 6 months in these patients (three with myelodysplastic 
syndrome [MDS]; one each with aplastic syndrome [AA], liver 
cirrhosis, heart failure with valvular heart disease, and accom-
panied malignancy; six lost to follow-up). 
We collected baseline data for clinical and endoscopic char-
acteristics, comorbidities, gastrointestinal surgical history, fam-
ily history, extraintestinal manifestations, Disease Activity Index 
for Intestinal Behçet’s Disease (DAIBD)21 at time of enrollment 
(June 2011), and any treatment for intestinal BD and anemia. 
Laboratory data was obtained at baseline and 6 months later, 
and included white blood cell count, hemoglobin, hematocrit, 
platelet, mean cell volume, mean corpuscular hemoglobin con-
centration (MCHC), red cell distribution width (RDW), albumin, 
erythrocyte sedimentation rate (ESR), and C-reactive protein 
(CRP). To investigate the type of anemia, serum iron, total iron 
binding capacity, transferrin saturation (TSAT), vitamin B12, fo-
late and reticulocyte count were obtained at time of enrollment. 
At 6-month follow-up, hemoglobin levels of all patients were 
assessed. We chose the 6-month follow-up interval to evaluate 
the improvement of anemia because the hemoglobin level usu-
ally returns to normal by 6 to 8 weeks after taking oral iron.
We used DAIBD to evaluate disease activity in patients with 
intestinal BD. DAIBD is comprised of the following eight vari-
ables: general well-being, fever, extra-intestinal manifestations, 
abdominal pain, abdominal masses, intestinal complications, 
and number of liquid stools in 1 week. The DAIBD was used 
to classify disease into quiescent (≤19), mild (20–39), moderate 
(40–74), or severe (≥75) categories.21
2. Definitions of anemia
Anemia was defined according to the World Health Organiza-
tion criteria: in men as hemoglobin <13 g/dL and in nonpreg-
nant women as hemoglobin <12 g/dL. Iron deficiency anemia 
(IDA) was defined as a ferritin <30 µg/L when the correspond-
ing CRP was <10 mg/L, or a ferritin <100 ng/mL when the CRP 
>10 mg/L and/or TSAT <16%.22 Anemia of chronic disease (ACD) 
was defined as anemia in the presence of a CRP-adjusted, nor-
mal, or increased serum ferritin and/or a low plasma iron and 
iron binding capacity.23 Vitamin B12 deficiency was defined as 
serum vitamin B12 <180 pg/mL, and folate deficiency as serum 
folate <2.34 ng/mL.
3. Statistical analysis
Continuous variables were expressed as the mean±standard 
deviation. Baseline characteristics of the nonanemia and anemia 
groups were compared using a Student t-test for continuous 
variables and a chi-square test (or Fisher exact test) for categori-
cal variables. In multivariate analysis, logistic regression analy-
sis was used to analyze associative factors of anemia in intesti-
nal BD. Age, sex and the variables for which p<0.1 in univariate 
analysis except laboratory data were included in multivariate 
analysis.
Results were considered statistically significant when p<0.05. 
All statistical analyses were performed using SPSS version 18.0 
(SPSS Inc., Chicago, IL, USA).
RESULTS
1. Patient characteristics
From June 1, 2011 to June 30, 2011, a total of 64 patients 
with intestinal BD enrolled in our study. The baseline charac-
teristics at diagnosis are summarized in Table 1. The mean age 
was 46.12±12.40 years, and 31.3% were male. Among these 64 
patients, anemia was detected in 26 patients (40.6%). Twenty-
three patients (35.9%) underwent more than one gastrointestinal 
surgery, including ileocecectomy (13) and right hemicolectomy 
(9). The mean DAIBD value was 37.73±32.39 in June 2011; 
based on DAIBD, eight patients had severe, 22 had moderate, 
nine had mild, and 25 had quiescent disease in June 2011. In 
terms of laboratory data, the mean values of ESR, CRP, and 
hemoglobin level were 32.27±27.35 mm/hr, 11.19±21.16 mg/L, 
and 12.52±1.83 mg/dL, respectively.
The cause of anemia was investigated in eight of 26 patients 
with anemia (one with IDA, two with ACD, four with combined 
type of IDA and ACD, and the other one with undetermined 
type); oral ferrous medication was prescribed to four patients. 
There was no patient who was given intravenous iron and/or 
erythropoietin (EPO) in this study (Table 1).
2. Comparison of baseline characteristics with regard to 
anemia
The patients were divided into two groups by blood hemo-
globin level: those without (n=38) and those with anemia (n=26). 
A comparison of baseline characteristics is presented in Table 2. 
Most baseline characteristics, including age, sex, disease du-
ration, type and frequency of gastrointestinal operation and 
medication for BD were not significantly different between the 
two groups. However, the number of patients with moderate 
to severe disease activity in DAIBD was significantly greater in 
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the anemia group than in the nonanemia group (18/26 [69.2%] 
vs 12/38 [31.6%], p=0.003). Also, ESR and CRP, both thought 
to be associated with disease activity, were significantly higher 
in the anemia group than in the nonanemia group (46.15±34.0 
mm/hr vs 22.76±16.26 mm/hr, p=0.003; 17.31±21.98 mg/L vs 
6.41±19.99 mg/L, p=0.049, respectively). The anemia group had 
higher mean values of RDW (15.94%±2.70% vs 13.62%±1.43%, 
p<0.001) and platelet count (288.08±91.82×103/µL vs 231.45± 
59.66×103/µL, p<0.001) than the nonanemia group. Hemoglo-
bin (10.85±1.08 g/dL vs 13.67±1.26 g/dL, p<0.001), hematocrit 
(33.49%±3.25% vs 41.02%±3.32%, p<0.001), MCHC (31.95±1.58 
g/dL vs 33.62±1.40 g/dL, p=0.004), and albumin (3.91±0.57 g/dL 
vs 4.39±0.29 g/dL, p<0.001) were lower in the anemia group. 
The cause of anemia was investigated in only eight patients 
(30.8%) of the 26 with anemia, and oral ferrous medicines pre-
scribed to four (50%); these four were prescribed ferrous sulfate 
256 mg once or twice daily, and two (50%) were able to recover 
normal hemoglobin levels within 6 months. Overall hemoglobin 
levels in all patients after 6 months were lower (11.99±1.12 vs 
13.75±1.38, p<0.001), and anemia (14/26 [53.8%] vs 2/38 [5.3%], 
p<0.001) was more frequent in the initial anemia group (Table 2).
3. Factors predictive of anemia in intestinal BD according 
to multivariate analysis
In multivariate analysis adjusted for age, sex, number of 
GI operation, DAIBD and corticosteroids use, the independent 
factor predictive of anemia in patients with intestinal BD was 
moderate to severe DAIBD (odds ratio, 4.08; 95% confidence 
interval, 1.21 to 13.71; p=0.023). However, the number of previ-
ous gastrointestinal operation and corticosteroids use were not 
independent factors relating anemia to IBD (Table 3).
DISCUSSION
In the present study, we found the frequency, short-term 
prognosis, and predictive factors of anemia in intestinal BD 
patients for the first time. Anemia in patients with intestinal BD 
was detected as high as 40.6% in this study. Moreover, anemia 
was meaningfully associated with disease activity of intestinal 
BD.
Similar to anemia in patients with IBD, anemia in patients 
with intestinal BD can occur due to chronic disease, iron de-
ficiency, vitamin deficiency and treatment itself such as sul-
fasalazine, 5-aminosalicylic acid, and azathioprine. Despite, in 
this study, the number of patients who were surveyed the cause 
of anemia was small (8/26, 30.77%) in the anemia group, seven 
out of eight were associated with IDA and/or ACD. This finding 
was accordance with the result of a previous study in patients 
with IBD which showed that the main causes of anemia in IBD 
were mostly IDA, ACD, and a combination of both.9
In addition, our study showed that the anemia group had 
higher platelet count than the nonanemia group and it also 
Table 1. Baseline Characteristics of Patients with Intestinal Behçet’s 
Disease (n=64)
Characteristic Value
Age, yr
Sex, male/female 
Duration of intestinal BD, mo
GI operation
No. of GI operations
Type of GI operation (duplicates allowed)
   Appendectomy
   Small bowel resection
   Right hemicolectomy
   Ileocecectomy
   Anal fistulectomy
DAIBD
   Quiescent-mild (0–39)
   Moderate-severe (≥40)
Laboratory data
   WBC, /µL
   Hemoglobin, g/dL
   Hematocrit, %
   MCV, fL
   MCHC, g/dL
   RDW, %
   Platelet, ×103/µL
   Albumin, g/dL
   ESR, mm/hr
   CRP, mg/L
Intestinal BD medication (duplicates allowed)
   Sulfasalazine, mesalazine, 5-ASA
   Purine analogue
   Anti-TNF-α inhibitor
   Corticosteroids
Laboratory data of anemia 
   Ferritin (n=10)
   Serum iron, µg/dL
   TIBC, µg/dL
   TSAT, %
   Vitamin B12, pg/mL
   Folate, ng/mL
   Reticulocyte count, %
Iron replacement
   Oral ferrous
   Intravenous
   Erythropoietin
Hemoglobin after 6 mo, g/dL
46.12±12.4
20 (31.3)/44 (68.8)
80.03±61.84
23 (35.9)
0.64±21.96
6 (9.4)
5 (7.8)
9 (14.1)
13 (20.3)
2 (3.1)
37.73±32.39
34 (53.1)
30 (46.9)
5,961±2,737.6
12.52±1.83
37.96±4.96
91.63±9.26
32.62±1.56
14.57±2.33
254.45±78.88
4.20±0.48
32.27±27.35
11.19±21.16
62 (96.9)
22 (34.3)
1 (1.6)
15 (23.4)
78.24±119.26
64.9±39.17
293.5±109.46
28.8±26.96
640.57±376.93
9.26±6.08
1.73±0.75
4
0
0
13.03±1.54
Data are presented as mean±SD or number (%).
BD, Behçet’s disease; GI, gastrointestinal; DAIBD, Disease Activity 
Index for Intestinal Behçet’s Disease; WBC, white blood cell count; 
MCV, mean cell volume; MCHC, mean corpuscular hemoglobin 
concentration; RDW, red cell distribution width; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein; 5-ASA, 5-aminosalicylic 
acid; anti-TNF-α, anti-tumor necrosis factor α; TIBC, total iron bind-
ing capacity; TSAT, transferrin saturation.
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Table 2. Comparisons of Baseline Characteristics with Regard to Anemia
Characteristic Nonanemia group (n=380) Anemia group (n=26) p-value
Age, yr
Male sex
Medication
   NSAIDs
   Antiplatelet drug
Duration of intestinal BD, mo
GI operation
No. of GI operations
   0–1
   ≥2
Type of GI operation (duplicates allowed)
   Appendectomy
   Small bowel resection
   Right hemicolectomy
   Ileocecectomy
   Anal fistulectomy
DAIBD
   Quiescent-mild (0–39)
   Moderate-severe (≥40)
Laboratory data
   WBC, /µL
   Hemoglobin, g/dL
   Hematocrit, %
   MCV, fL
   MCHC, g/dL
   RDW, %
   Platelet, ×103/µL
   Albumin, g/dL
   ESR, mm/hr
   CRP, mg/L
Intestinal BD medication  (duplicates allowed)
   Sulfasalazine, mesalazine, 5-ASA
   Purine analogue
   Anti-TNF-α inhibitor
   Corticosteroids 
Anemia laboratory data
   Ferritin, ng/mL
   Serum iron, µg/dL
   TIBC, µg /dL
   TSAT, %
   Reticulocyte count, %
   Vitamin B12, pg/mL
   Folate, ng/mL
Iron replacement
   Oral ferrous
   Intravenous
   Erythropoietin
Hemoglobin after 6 mo, g/dL
Anemia after 6 mo
44.34±12.27
11 (28.9)
14 (36.8)
2 (5.3)
77.82±58.18
11 (28.9)
0.46±0.76
34 (61.8)
4 (44.4)
2 (5.3)
3 (7.9)
3 (7.9)
 6 (15.8)
1 (2.6)
30.26±30.36
26 (68.4)
12 (31.6)
5,424.47±1,998.12
13.67±1.26
41.02±3.32
91.26±7.09
33.62±1.40
13.62±1.43
231.45±59.66
4.39±0.29
22.76±16.26
6.41±19.99
36 (94.7)
13 (34.2)
0
6 (15.8)
(n=2)
58.10±38.33
49.50±12.02
258.50±34.65
19.00±1.41
1.86±1.0
(n=1)
808.0
3.02
0
0
0
13.75±1.38
2 (5.3)
48.73±12.36
9 (34.6)
11 (42.3)
1 (3.8)
83.27±67.89
12 (46.2)
0.96±1.71
21 (38.2)
5 (55.6)
4 (66.7)
2 (7.7)
6 (23.1)
7 (26.9)
1 (3.8)
48.65±32.73
8 (30.8)
18 (69.2)
6,745.38±3,449.61
10.85±1.08
33.49±3.25
92.16±11.88
31.95±1.58
15.94±2.70
288.08±91.82
3.91±0.57
46.15±34.0
17.31±21.98
26 (100)
9 (34.6)
1 (3.8)
9 (34.6)
(n=8)
83.28±133.91
68.75±43.21
302.25±121.64
31.25±30.0
1.70±0.76
(n=6)
612.67±404.91
10.30±5.94
4 (15.4)
0
0
11.99±1.12
14 (53.8)
0.166
0.783
0.660
0.641
0.732
0.159
0.090
0.467
0.213
>0.999
0.142
0.277
>0.999
0.024
0.003
0.087
<0.001
<0.001
0.732
0.004
<0.001
0.009
<0.001
0.003
0.049
0.510
0.973
0.406
0.081
0.807
0.566
0.642
0.596
0.807
0.674
0.308
0.024
<0.001
<0.001
Data are presented as mean±SD or number (%).
NSAIDs, nonsteroidal anti-inflammatory drugs; BD, Behçet’s disease; GI, gastrointestinal; DAIBD, Disease Activity Index for Intestinal Behçet’s Dis-
ease; WBC, white blood cell count; MCV, mean cell volume; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; 
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; 5-ASA, 5-aminosalicylic acid; anti-TNF-α, anti-tumor necrosis factor α; TIBC, total iron 
binding capacity; TSAT, transferrin saturation.
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accordance with previous studies of IBD. Several studies sug-
gest that platelets are involved in the pathogenesis of IBD and 
increased platelet count has been associated with disease activ-
ity in IBD.24-27 Moreover, reactive thrombocytosis has been as-
sociated in adults with iron deficiency anemia, inflammatory 
conditions.28 As a result, both inflammation and iron deficiency 
predisposes patients with BD as well as UC and CD to develop 
thrombocytosis.
Interestingly, BD, which is predominantly associated with 
MDS,29 is highly relevant to anemia itself. In such cases those 
are associated with MDS, patients with BD demonstrate more 
frequent gut involvement, and were associated with trisomy 8 
in their bone marrow.30,31 Besides MDS, there may also be an as-
sociation between BD and bone marrow failure, such as in AA. 
Consistent with these findings, there were three patients (3/87, 
3.45%) with MDS and one patient (1/87, 1.15%) with AA who 
were initially excluded in this study. 
Furthermore, despite the exclusion of patients with bone 
marrow failure-related anemia, this study showed that the fre-
quency of anemia in intestinal BD patients (40.6%) remained as 
high as that of patients with CD and UC.9-11
The ultimate therapeutic goal for intestinal BD patients with 
anemia is improvement in quality of life; however, in this study, 
the only objective measures we can gather are changes in labo-
ratory data, including hemoglobin concentrations. In anemic 
cancer patients, improvements in quality of life were reported 
beginning at hemoglobin levels of up to 14 g/dL.32 Since BD pa-
tients are younger, on average, than cancer patients, they may 
experience higher physical and cognitive demands; thus, nor-
malization of hemoglobin levels (12.0 g/dL in women and 13.0 
g/dL in men) in patients with intestinal BD should be considered 
as for the goal of treatment of anemia in CD and UC patients.9
According to multivariate analysis, intestinal BD patients 
with moderate to severe DAIBD are likely to have anemia. This 
is a similar finding with IBD patients. In IBD patients, previous 
studies showed that the higher disease activity was associated 
with lower hemoglobin and hematocrit level and this phenom-
enon was explained as inflammation inhibits iron absorption 
and links to abnormal iron homeostasis.13,33 Physicians should 
evaluate the causes and types of anemia, and aggressively man-
age the intestinal BD patients with anemia using intravenous 
iron and/or EPO in order to prevent the increase of frequency of 
anemia and identify malignant conditions such as MDS or AA.
There were several limitations in our study. First, it was a 
retrospective, cross-sectional, case-control study that was based 
on medical record review. Nevertheless, we sought to identify 
predictive factors of anemia by analyzing a well-organized, 
computer-based medical database. Secondly, data were collected 
from a single hospital that was part of a tertiary referral center. 
This might cause our patient group to differ from the general 
population of Koreans with BD. Due to its rarity and challenging 
diagnosis, however, most BD patients were managed in tertiary 
university hospitals rather than primary or secondary medical 
centers in Korea, and our medical center follows up the largest 
number of the patients with intestinal BD in Korea. As such, the 
patient group in this study could show less bias, though patients 
were recruited from a single tertiary university hospital.
In conclusion, the frequency of anemia in patients with in-
testinal BD was as high as that of patients with CD and UC. 
However, the importance of anemia in intestinal BD patients is 
still overlooked in clinical practice. Therefore, we suggest that 
physicians pay particular attention to anemia in patients with 
intestinal BD, in order to improve patient quality of life and 
monitor for serious underlying problems, such as MDS and AA.
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